Poxel SA Total Liabilities
Poxel SA total liabilities. Based on the latest financial reports, Poxel SA (POXEL) has total liabilities worth €66.41 Million EUR (≈ $77.63 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Poxel SA's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Poxel SA (2010–2024)
Total liabilities of Poxel SA from 2010 to 2024. This chart illustrates how Poxel SA's total liabilities have evolved over time, based on quarterly financial data. Explore Poxel SA (POXEL) long-term investment share to see how much of total assets are deployed in long-term investments.
Poxel SA Competitors by Total Liabilities
The table below lists competitors of Poxel SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thai Poly Acrylic Public Company Limited
BK:TPA
|
Thailand | ฿167.45 Million |
|
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
|
USA | $201.59 Million |
|
Kim Hin Joo
KLSE:0210
|
Malaysia | RM23.55 Million |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
India | Rs-691.15 Million |
|
Agrimin Ltd
AU:AMN
|
Australia | AU$11.41 Million |
|
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
|
China | CN¥477.34 Million |
|
Esthetics International Group
KLSE:5081
|
Malaysia | RM103.77 Million |
|
Spineguard
PA:ALSGD
|
France | €4.07 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Poxel SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see POXEL asset base.
Liquidity & Leverage Metrics
Poxel SA Total Liabilities Ratios Explained
Poxel SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 13.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Poxel SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Poxel SA (2010–2024)
The table below shows the annual total liabilities of Poxel SA from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €73.87 Million ≈ $86.36 Million |
+37.04% |
| 2023-12-31 | €53.90 Million ≈ $63.02 Million |
+1.79% |
| 2022-12-31 | €52.95 Million ≈ $61.91 Million |
+13.44% |
| 2021-12-31 | €46.68 Million ≈ $54.58 Million |
+22.21% |
| 2020-12-31 | €38.20 Million ≈ $44.66 Million |
+15.19% |
| 2019-12-31 | €33.16 Million ≈ $38.77 Million |
-33.33% |
| 2018-12-31 | €49.73 Million ≈ $58.14 Million |
+4.87% |
| 2017-12-31 | €47.43 Million ≈ $55.45 Million |
+334.37% |
| 2016-12-31 | €10.92 Million ≈ $12.76 Million |
+23.79% |
| 2015-12-31 | €8.82 Million ≈ $10.31 Million |
-46.13% |
| 2014-12-31 | €16.37 Million ≈ $19.14 Million |
-49.27% |
| 2013-12-31 | €32.28 Million ≈ $37.73 Million |
+310.22% |
| 2012-12-31 | €7.87 Million ≈ $9.20 Million |
+178.30% |
| 2011-12-31 | €2.83 Million ≈ $3.31 Million |
+33.66% |
| 2010-12-31 | €2.12 Million ≈ $2.47 Million |
-- |
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more